KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to -$184.0 million.

  • Boston Scientific's Cash from Financing Activities fell 18598.13% to -$184.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$395.0 million, marking a year-over-year decrease of 12177.51%. This contributed to the annual value of -$395.0 million for FY2025, which is 12177.51% down from last year.
  • As of Q4 2025, Boston Scientific's Cash from Financing Activities stood at -$184.0 million, which was down 18598.13% from -$104.0 million recorded in Q3 2025.
  • Over the past 5 years, Boston Scientific's Cash from Financing Activities peaked at $1.6 billion during Q1 2024, and registered a low of -$344.0 million during Q2 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was $1.5 million (2021), whereas its average is $39.0 million.
  • Per our database at Business Quant, Boston Scientific's Cash from Financing Activities plummeted by 1730000.0% in 2022 and then skyrocketed by 237391.3% in 2024.
  • Quarter analysis of 5 years shows Boston Scientific's Cash from Financing Activities stood at -$8.0 million in 2021, then soared by 112.5% to $1.0 million in 2022, then surged by 1400.0% to $15.0 million in 2023, then surged by 1326.67% to $214.0 million in 2024, then tumbled by 185.98% to -$184.0 million in 2025.
  • Its Cash from Financing Activities was -$184.0 million in Q4 2025, compared to -$104.0 million in Q3 2025 and -$340.0 million in Q2 2025.